OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• OptimizeRx has a “Moderate Buy” consensus rating from nine analysts: six buys, two holds and one sell. The average 12-month price target is $11.43, above the reported share price of $7.29.
• The company exceeded quarterly expectations, reporting EPS of $0.16 versus the $0.11 consensus and revenue of $20.50 million versus $20.20 million expected.
• Institutional investors own 76.47% of OptimizeRx, with several hedge funds increasing their positions; Next Century Growth Investors made the largest reported increase at 139.8%.

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $11.4286.

OPRX has been the subject of several research analyst reports. Stifel Nicolaus set a $12.00 price objective on OptimizeRx in a research report on Thursday, August 13th. Wall Street Zen lowered OptimizeRx from a "strong-buy" rating to a "buy" rating in a research note on Monday, July 20th. Citigroup reaffirmed a "market outperform" rating on shares of OptimizeRx in a report on Friday, August 14th. Citizens Jmp upped their price target on shares of OptimizeRx from $9.00 to $11.00 and gave the stock a "market outperform" rating in a research report on Friday, August 14th. Finally, UBS Group set a $11.00 price objective on shares of OptimizeRx in a report on Friday, August 14th.

OptimizeRx Stock Performance

NASDAQ OPRX opened at $7.29 on Friday. OptimizeRx has a 1-year low of $4.54 and a 1-year high of $22.25. The company has a 50 day moving average of $7.26 and a 200-day moving average of $6.43. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14. The firm has a market cap of $137.34 million, a price-to-earnings ratio of 31.70 and a beta of 1.09.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.11 by $0.05. The business had revenue of $20.50 million for the quarter, compared to the consensus estimate of $20.20 million. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%. On average, equities analysts forecast that OptimizeRx will post 0.51 earnings per share for the current fiscal year.

Institutional Trading of OptimizeRx

Hedge funds have recently modified their holdings of the stock. Royce & Associates LP raised its position in OptimizeRx by 0.7% in the 4th quarter. Royce & Associates LP now owns 682,030 shares of the company's stock worth $8,362,000 after purchasing an additional 4,700 shares during the last quarter. Rice Hall James & Associates LLC boosted its position in OptimizeRx by 8.2% in the 4th quarter. Rice Hall James & Associates LLC now owns 590,674 shares of the company's stock valued at $7,242,000 after buying an additional 44,858 shares during the last quarter. Next Century Growth Investors LLC boosted its position in OptimizeRx by 139.8% in the 4th quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company's stock valued at $6,196,000 after buying an additional 294,688 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in OptimizeRx by 22.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company's stock valued at $3,540,000 after buying an additional 102,661 shares during the last quarter. Finally, AWM Investment Company Inc. acquired a new stake in shares of OptimizeRx in the 2nd quarter valued at $1,375,000. 76.47% of the stock is owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation NASDAQ: OPRX is a digital health company that provides technology and data-driven engagement solutions for life sciences companies, healthcare providers and patients. Its platform is designed to support communication across the healthcare journey, helping pharmaceutical and biotechnology companies connect with clinicians and patients through digital channels.

The company's solutions include point-of-care messaging, patient savings and financial assistance programs, medication adherence and support services, and analytics and audience-engagement tools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.